Advantages of analysing both pairwise SNV-distance and differing SNVs between Mycobacterium tuberculosis isolates for recurrent tuberculosis cause determination
- PMID: 36951900
- PMCID: PMC10132068
- DOI: 10.1099/mgen.0.000956
Advantages of analysing both pairwise SNV-distance and differing SNVs between Mycobacterium tuberculosis isolates for recurrent tuberculosis cause determination
Abstract
Endogenous reactivation and exogenous reinfection are two possible causes of recurrent tuberculosis (TB). However, in some cases, precise cause determination can be challenging. In this study, we used whole genome sequencing to determine pairwise SNV distances and detect differing SNVs in initial and subsequent isolates for recurrent TB cases when the first and second episodes were caused by Mycobacterium tuberculosis (Mtb) strains with an identical spoligotype pattern. In total, 104 Mtb isolates from 36 recurrent TB and 16 single TB episode patients were included in the study. Most isolate pairs belonged to the SIT1 (n=21), SIT42 (n=9), SIT53 (n=9), and SIT254 (n=7) spoligotypes, and in 27 cases, resistance to at least one anti-TB drug was found in either isolate. Drug susceptibility was more common in the recurrent TB patient cohort, and longitudinal single TB episode isolates were more prone to be drug-resistant (p=0.03), while the association between patient cohort and spoligotype was not statistically significant (p=0.07). The pairwise SNV-distance between the longitudinal single TB episode isolates was small (0-7 SNVs). Among the recurrent TB isolates, based on the high SNV-distance (38-273 SNVs), six reinfection cases (16.7%) were identified. This distance was small (<10 SNVs) in the remaining 30 isolate pairs. Further analysis of differing SNVs revealed that 22 (61.1%) cases could be classified as possible reactivation. Notably, despite the small distance of 2-7 SNVs, initial isolates of eight patients (22.2%) had several SNVs that were not found in the second isolates; therefore, these cases were classified as reinfection with a closely related Mtb strain. No statistically significant difference in the time interval between specimen collection in the reactivation and reinfection Mtb sample groups (p=0.13) or an association between recurrence cause and drug resistance status (p=0.62) or spoligotype (p=0.79) could be detected. The mycobacterial median mutation rate of longitudinal single TB episodes and possible reactivation isolate pairs (n=37) was 0.12 SNVs/genome/year (IQR 0-0.39), and in 18 cases (48.6%), it was equal to zero. No statistically significant differences in mutation rate were found between recurrent TB and longitudinal single TB episode isolates (p=0.087), drug-susceptible and resistant isolates (p=0.37) or isolates of Beijing and other genotype families (p=0.33). Furthermore, four cases of fluoroquinolone resistance development through the acquired SNVs in the gyrA gene were identified. To conclude, this study highlighted the complexity of recurrent episode cause determination and showed the usefulness of differing SNV identification in both Mtb isolates in such cases. Expected drug susceptibility was the only discriminative factor for recurrent TB episode-causing mycobacterial strains, while no differences between reactivation and reinfection sample groups could be identified.
Keywords: reactivation; recurrence; reinfection; tuberculosis; whole genome sequencing.
Conflict of interest statement
The authors declare that there are no conflicts of interest.
Figures






Similar articles
-
Recurrence of tuberculosis in a low-incidence setting: a retrospective cross-sectional study augmented by whole genome sequencing.BMC Infect Dis. 2018 Jun 7;18(1):265. doi: 10.1186/s12879-018-3164-z. BMC Infect Dis. 2018. PMID: 29879906 Free PMC article.
-
A retrospective genomic analysis of drug-resistant strains of M. tuberculosis in a high-burden setting, with an emphasis on comparative diagnostics and reactivation and reinfection status.BMC Infect Dis. 2020 Jan 7;20(1):17. doi: 10.1186/s12879-019-4739-z. BMC Infect Dis. 2020. PMID: 31910804 Free PMC article.
-
Whole Genome Sequencing Assessing Impact of Diabetes Mellitus on Tuberculosis Mutations and Type of Recurrence in India.Clin Infect Dis. 2022 Sep 14;75(5):768-776. doi: 10.1093/cid/ciab1067. Clin Infect Dis. 2022. PMID: 34984435 Free PMC article.
-
[Development of antituberculous drugs: current status and future prospects].Kekkaku. 2006 Dec;81(12):753-74. Kekkaku. 2006. PMID: 17240921 Review. Japanese.
-
The management of tuberculosis: epidemiology, resistance and monitoring.Dan Med Bull. 2010 Nov;57(11):B4213. Dan Med Bull. 2010. PMID: 21055374 Review.
Cited by
-
Discordance Between Phenotypic and WGS-Based Drug Susceptibility Testing Results for Some Anti-Tuberculosis Drugs: A Snapshot Study of Paired Mycobacterium tuberculosis Isolates with Small Genetic Distance.Infect Drug Resist. 2024 Aug 1;17:3289-3307. doi: 10.2147/IDR.S468997. eCollection 2024. Infect Drug Resist. 2024. PMID: 39108991 Free PMC article.
-
Clinical Mycobacterium tuberculosis isolates exhibit a molecular clock rate below 1 SNP per genome per year.Front Microbiol. 2025 Jun 13;16:1591792. doi: 10.3389/fmicb.2025.1591792. eCollection 2025. Front Microbiol. 2025. PMID: 40584032 Free PMC article.
-
Unraveling tuberculosis patient cluster transmission chains: integrating WGS-based network with clinical and epidemiological insights.Front Public Health. 2024 May 20;12:1378426. doi: 10.3389/fpubh.2024.1378426. eCollection 2024. Front Public Health. 2024. PMID: 38832230 Free PMC article.
-
Endogenous reactivation cases identified by whole genome sequencing of Mycobacterium tuberculosis: Exploration of possible causes in Latvian tuberculosis patients.J Clin Tuberc Other Mycobact Dis. 2024 Oct 31;37:100493. doi: 10.1016/j.jctube.2024.100493. eCollection 2024 Dec. J Clin Tuberc Other Mycobact Dis. 2024. PMID: 39559709 Free PMC article.
-
Characterizing the Etiology of Recurrent Tuberculosis Using Whole Genome Sequencing: Alaska, 2008-2020.J Infect Dis. 2025 Feb 4;231(1):94-102. doi: 10.1093/infdis/jiae275. J Infect Dis. 2025. PMID: 38794931 Free PMC article.
References
-
- World Health Organization Global tuberculosis report 2021. Geneva: World Health Organization. Licence: CC BY-NC-SA 3.0 IGO. 2021.
-
- World Health Organization Implementing the end TB strategy: the essentials. Geneva: World Health Organization. Licence: CC BY-NC-SA 3.0 IGO. 2015.
-
- World Health Organization Meeting report of the WHO expert consultation on drug-resistant tuberculosis treatment outcome definitions 17-19 November 2020. Geneva: World Health Organization; 2021. Licence: CC BY-NC-SA 3.0 IGO. 2020.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical